Phenylbutyrate sodium

HDAC inhibitor



BML-EI320-0001	1 g	89.00 USD
Do you need bulk/larger quantities?

Replaces Prod. #: ALX-270-303

Weak histone deacetylase (HDAC) inhibitor. Induces differentiation, growth arrest and apoptosis in a number of cell lines. Protects against cerebral ischemic injury and displays neuroprotective effect in a mouse model of Huntington’s disease. Anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation. Shows chemical chaperone activity.

Product Details

Alternative Name:	Sodium 4-phenylbutyrate, 4-Phenylbutyric acid sodium salt, SBP, 4PBA, PBNa

Formula:	C₁₀H₁₁O₂ . Na

MW:	186.2

CAS:	1716-12-7

Purity:	≥98% (UHPLC)

Appearance:	White to yellowish solid.

Solubility:	Soluble in DMSO or water (25mg/ml).

Shipping:	Ambient

Long Term Storage:	Ambient

Use/Stability:	Stable for at least 1 year after receipt when stored at +20°C. Stock solutions are stable for up to 3 months at -20°C.

Handling:	Hygroscopic.

Regulatory Status:	RUO - Research Use Only

Please mouse over

Product Literature References

Phenylbutyrate - a pan-HDAC inhibitor - suppresses proliferation of glioblastoma LN-229 cell line: M. Kuszaczuk, et al.; Tumour Biol. 37, 931 (2016), Application(s): Cell culture, Abstract; Full Text

Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells: K. Huber, et al.; J. Biol. Chem. 286, 22211 (2011), Abstract; Full Text

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease: G. Gardian, et al.; J. Biol. Chem. 280, 556 (2005), Abstract; Full Text

Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells: I.B. Appelskog, et al.; Int. J. Oncol. 24, 1419 (2004), Abstract;

Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway: X. Zhang, et al.; J. Cell. Biochem. 93, 819 (2004), Abstract;

Sodium 4-phenylbutyrate protects against cerebral ischemic injury: X. Qi, et al.; Mol. Pharmacol. 66, 899 (2004), Abstract; Full Text

Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.": Y. Sowa & T. Sakai; Biofactors 12, 283 (2000), Abstract;

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors: S.D. Gore & M.A. Carducci; Expert Opin. Investig. Drugs 9, 2923 (2000), Abstract;

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase: R.P. Warrell, et al.; J. Natl. Cancer Inst. 90, 1621 (1998), Abstract;

Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase: M.A. Lea & N. Tulsyan; Anticancer Res. 15, 879 (1995), Abstract;